Retro-analysis of wavefront-optimised myopic LASIK eyes: theoretical topography-modified refraction (TMR) calculation, instead of the clinical refraction used, and the potential influence it may have had in visual acuity, corneal trefoil and coma
Session Details
Session Title: LASIK II
Session Date/Time: Tuesday 25/09/2018 | 16:30-18:00
Paper Time: 17:16
Venue: Room A3, Podium 2
First Author: : A.Kanellopoulos GREECE
Co Author(s): :
Abstract Details
Purpose:
The purpose of this study was to compare the long term efficacy, safety and predictability of wavefront-optimized (WFO) and hypothetical topography-guided treatment in patients having laser in situ keratomileusis (LASIK) for myopia.
Setting:
LaserVision.gr Clinical and Research Eye Institute, Athens, Greece
Methods:
In this retrospective, non-comparative case series, 200 eyes (one hundred patients) have undergone myopic (with corresponding astigmatism) wavefront-optimized LASIK using Alcon Wavelight EX500 excimer laser (Alcon Laboratories, Inc.). The 12 months post-operative refractive visual outcomes and ocular aberration changes were compared to the pre-operative values. Pre-operative topography data were used to generate hypothetical treatment data (third HOAs and individual terms) if topography-guided (TG) with TMR cylinder amount and axis adjustment was used instead of WFO and compared to the current data.
Results:
After at least 12 months follow-up these wavefront optimized myopic LASIK cases were evaluated had UDVA of 20/22 and CDVA of 20/20. The postoperative refractive error in Diopters was -0.20 ± 0.46 sphere and - 0.45 ± 0.27 cylinder. Population average 3rd order aberrations coma and trefoil values preoperatively were zero, while 12 months postoperatively the mean 3rd order RMS (root mean square) value was 0.67 ± 0.41 um.
Conclusions:
Topography-modified refraction in topography-guided LASIK may offer improved outcomes through reduction of coma and trefoil, more accurate cylinder correction. Angle kappa and/or accommodative cylinder may bias standard clinical refractions.
Financial Disclosure:
-